Agendia Level 1B Evidence Shows MammaPrint® is the First and Only FDA-cleared Gene Expression Profiling Test to Predict Benefit from Extended Endocrine Therapy in Early-Stage Breast Cancer Patients

IRVINE, Calif. & AMSTERDAM–(BUSINESS WIRE)–Agendia, Inc., a leader in gene expression profiling for early-stage breast cancer, today announced it will present late-breaking research at the 2022 San Antonio Breast Cancer Symposium (SABCS) that proves MammaPrint is the first FDA-cleared gene expression profiling test to predict an early-stage breast cancer patient’s…